Evidence map›Paper›PMID 32618242›Full record

Trial reportThe American journal of tropical medicine and hygiene2020

Assessment of the Acceptability of Testing and Treatment during a Mass Drug Administration Trial for Malaria in Zambia Using Mixed Methods.

Kafula Silumbe, Timothy P Finn, Todd Jennings, Chilumba Sikombe, Elizabeth Chiyende, Busiku Hamainza, Elizabeth Chizema Kawesha, Thomas P Eisele, Duncan Earle, Richard W Steketee and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02329301 (Assessing the Effectiveness of Mass Drug Administration), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02329301 nacompletednot on this map

Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

TypeinterventionalSponsorPATHRan2014 to 2020Enrolled2,430ConditionsMalaria, Malaria, FalciparumArmsMDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Mass Drug Administration: Contextual Factor Considerations.The American journal of tropical medicine and hygiene · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kafula Silumbe1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Timothy P Finn2Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Todd Jennings1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Chilumba Sikombe1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Elizabeth Chiyende1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Busiku Hamainza3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Elizabeth Chizema Kawesha3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Thomas P Eisele2Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Duncan Earle1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Richard W Steketee1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
John M Miller1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
National HIV/AIDS/STI/TB Council · ZMMinistry of Health · ZMTulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From 2014 to 2016, a community-randomized controlled trial in Southern Province, Zambia, compared mass drug administration (MDA) and focal MDA (fMDA) with the standard of care. Acceptability of the intervention was assessed quantitatively using closed-ended and Likert scale-based questions posed during three household surveys conducted from April to May in 2014, 2015, and 2016 in 40 health catchments that implemented MDA and fMDA and 20 catchments that served as trial controls. In 2014 and 2015, 47 households per catchment were selected, targeting 1,880 households in MDA and fMDA trial arms; in 2016, 55 households per catchment were selected for a target of 2,200 households in MDA and fMDA trial arms. Concurrently, 27 focus group discussions and 23 in-depth interviews with 248 participants were conducted on reasons for testing and treatment refusal, reasons for nonadherence, and community perception of the MDA campaign. Results demonstrated that the MDA campaign was highly accepted with more than 99% of respondents stating that they would take treatment if positive for malaria. High acceptability at baseline could be associated with test-and-treat campaigns recently conducted in the study area. There was a large increase in the acceptability of prophylactic treatment if negative for malaria from the baseline to follow-up survey for adults and children, from 62% to 96% for each. This likely resulted from an intensive community-wide sensitization program that occurred before the first treatment round at each household during community health worker visits.

Indexed as

Attitude to HealthMass Drug AdministrationPatient Acceptance of Health CareAdultArtemisininsDisease EradicationDrug Therapy, CombinationFemaleFocus GroupsHumansMalaria, FalciparumMaleMedication AdherenceMiddle AgedPiperazinesQuinolinesArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID32618242
PMCPMC7416978
OpenAlexW3039574251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.